Grace Therapeutics, Inc. (GRCE)
| Market Cap | 38.73M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.79M |
| Shares Out | 16.27M |
| EPS (ttm) | -0.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 269,627 |
| Open | 2.330 |
| Previous Close | 2.370 |
| Day's Range | 2.320 - 2.450 |
| 52-Week Range | 1.790 - 5.180 |
| Beta | 0.36 |
| Analysts | Strong Buy |
| Price Target | 5.95 (+150.0%) |
| Earnings Date | Jun 18, 2026 |
About GRCE
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The co... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for GRCE stock is "Strong Buy." The 12-month stock price target is $5.95, which is an increase of 150.00% from the latest price.
News
Grace Therapeutics reports FY26 EPS (47c) vs (79c) last year
“Since receipt of the U.S. Food and Drug Administration’s (FDA) Complete Response Letter in April 2026, we have been working diligently on addressing the cited items, and we look forward…
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined Pr...
Grace Therapeutics Annual report: Q4 2026
Grace Therapeutics has published its Q4 2026 annual report on June 18, 2026.
Grace Therapeutics Earnings release: Q4 2026
Grace Therapeutics released its Q4 2026 earnings on June 18, 2026, summarizing the period's financial results.
Grace Therapeutics Slides: Corporate presentation
Grace Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 18, 2026.
Grace Therapeutics price target lowered to $4 from $11 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on Grace Therapeutics (GRCE) to $4 from $11 and keeps a Buy rating on the shares following the CRL to GTx-104. FDA cited CMC…
Grace Therapeutics price target lowered to $8 from $12 at TD Cowen
TD Cowen analyst Stacy Ku lowered the firm’s price target on Grace Therapeutics (GRCE) to $8 from $12 and keeps a Buy rating on the shares. The firm said GTx-104’s…
Grace Therapeutics down 48% after receipt of CRL from FDA for GTx-104
Shares of Grace Therapeutics (GRCE) are down $2.07, or 48%, to $2.24 after the FDA issued a Complete Response Letter for the company’s New Drug Application for GTx-104 for the…
Grace Therapeutics, Inc trading resumes
13:45 EDT Grace Therapeutics (GRCE), Inc trading resumes
US FDA declines to approve Grace Therapeutics' drug for a type of stroke
Grace Therapeutics said on Thursday the U.S. Food and Drug Administration declined to approve its drug for a rare type of stroke.
Grace Therapeutics issued Complete Response Letter from FDA
Grace Therapeutics (GRCE) announced that the U.S. Food and Drug Administration has issued a Complete Response Letter for the company’s New Drug Application for GTx-104 for the treatment of patients…
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information
Grace Therapeutics, Inc trading halted, news pending
12:27 EDT Grace Therapeutics (GRCE), Inc trading halted, news pending
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, no...
Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences
PRINCETON, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, no...
Grace Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
GTx-104, an IV formulation of nimodipine for aSAH, demonstrated superior dose compliance, fewer hypotensive events, and better recovery outcomes versus oral forms in the STRIVE-ON trial. Regulatory review is progressing, with launch preparations focused on key hospitals and broad market education.
Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
PRINCETON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, nov...
Grace Therapeutics Slides: Corporate presentation
Grace Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on February 13, 2026.
Grace Therapeutics Earnings release: Q3 2026
Grace Therapeutics released its Q3 2026 earnings on February 12, 2026, summarizing the period's financial results.
Grace Therapeutics Quarterly report: Q3 2026
Grace Therapeutics has published its Q3 2026 quarterly earnings report on February 12, 2026.
Grace Therapeutics reports Q3 EPS (14c) vs (36c) last year
“During our third quarter of fiscal 2026 we continued to execute on our clinical and corporate goals, led by our pre-commercial planning in anticipation of potential FDA approval of our…
Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update
FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 STRIVE-ON ...
Grace Therapeutics Slides: Corporate Presentation
Grace Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 30, 2025.
Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference
PRINCETON, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, nov...
Grace Therapeutics reports Q2 EPS (6c) vs (30c) last year
“During our second quarter of 2026 we continued to execute on our clinical and corporate goals, led by FDA acceptance for review of our NDA for GTx-104 for the treatment…